

**Amendments to the Claims:**

Cancel claims 1 and 2, and amend the remaining claims as follows.

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Canceled).

2. (Canceled).

3. (Currently Amended) ~~The method of claim 2 wherein,~~ A method of treating abdominal cancer comprising performing a surgery on a patient's abdomen by forming a surgical opening in said patient's abdomen, surgically removing a cancerous tumor from the patient's abdomen through the surgical opening, and closing said surgical opening, the method including a step of administering taurolidine, taurultam or a mixture thereof to the patient's abdomen prior to said closing of said surgical opening and after said surgically removing said cancerous tumor, so as to treat cancer in the patient's abdomen, further including a step of additionally administering taurolidine, taurultam or a mixture thereof to said patient after said closing said surgical opening wherein, after closing said surgical opening, said taurolidine, taurultam or mixture thereof is administered to said patient by installation or intravenous infusion, further including the step of additionally administering taurolidine, taurultam or a mixture thereof to said patient prior to forming said surgical opening in said patient's abdomen.

4. (Currently Amended) ~~The method of claim 1,~~ A method of treating abdominal cancer comprising performing a surgery on a patient's abdomen by forming a surgical opening in said patient's abdomen, surgically removing a cancerous tumor from the patient's abdomen through the surgical opening, and closing said surgical opening, the method including a step of administering taurolidine, taurultam or a mixture thereof to the patient's abdomen prior to said closing of said surgical opening and after said surgically removing said cancerous tumor, so as to treat cancer in the patient's abdomen, further including a step of additionally administering

taurolidine, taurultam or a mixture thereof to said patient after said closing said surgical opening;  
further including the step of additionally administering taurolidine, taurultam or a mixture thereof  
to said patient prior to forming said surgical opening in said patient's abdomen.

5. (Currently Amended) The method of claim ~~14~~, wherein performing said surgery on  
said patient includes introducing a trocar tube into said patient during laparoscopic tumor surgery  
so as to conduct laparoscopic tumor surgery so as to conduct laparoscopic tumor surgery utilizing  
said trocar tube.

6. (Previously presented) The method of claim 5 wherein during said surgery, said  
administering said taurolidine, taurultam or mixture thereof to said patient's abdomen is  
conducted by passing a solution containing said taurolidine, taurultam or mixture thereof through  
said trocar tube so as to contact internal tissue of the patient with said solution.

7. (Previously presented) The method of claim 6 further comprising the step of  
withdrawing said trocar from said patient prior to said closing said surgical opening and prior to  
said step of additionally administering said taurolidine, taurultam or mixture thereof to said  
patient after closing said surgical opening.

8. (Currently Amended) The method of claim ~~14~~ wherein said taurolidine, taurultam or a  
mixture thereof is present in a solution containing from 0.5 to 3% by weight said taurolidine or  
from 2 to 3% by weight said taurultam, or a mixture thereof.

9. (Previously presented) The method of claim 8 wherein said solution further contains  
heparin, a heparin derivative or hyaluronic acid.

10. (Currently Amended) ~~The method of claim 6~~ A method of treating abdominal cancer  
comprising performing a surgery on a patient's abdomen by forming a surgical opening in said  
patient's abdomen, surgically removing a cancerous tumor from the patient's abdomen through  
the surgical opening, and closing said surgical opening, the method including a step of  
administering taurolidine, taurultam or a mixture thereof to the patient's abdomen prior to said

closing of said surgical opening and after said surgically removing said cancerous tumor, so as to treat cancer in the patient's abdomen, further including a step of additionally administering taurolidine, taurultam or a mixture thereof to said patient after said closing said surgical opening, wherein performing said surgery on said patient includes introducing a trocar tube into said patient during laparoscopic tumor surgery so as to conduct laparoscopic tumor surgery so as to conduct laparoscopic tumor surgery utilizing said trocar tube, wherein during said surgery, said administering said taurolidine, taurultam or mixture thereof to said patient's abdomen is conducted by passing a solution containing said taurolidine, taurultam or mixture thereof through said trocar tube so as to contact internal tissue of the patient with said solution, further comprising the step of additionally introducing said solution into said patient prior to said laparoscopic tumor surgery and prior to introducing said trocar tube into said patient.

11. (Previously presented) The method of claim 5 wherein said cancerous tumor is selected from the group consisting of oesophagus carcinoma, cardiacarcoma, malignant degenerative ulcer, stomach carcinoma, antrum carcinoma, corpus carcinoma, align adenoma of island cells, gall duct carcinoma, distal choledochus carcinoma, pancreas head carcinoma, pancreas papilla carcinoma, pancreas corpus carcinoma, pancreas cauda carcinoma, small intestinal tract carcinoma, large intestinal tract carcinoma, sarcoma, colon malignancy, adeno carcinoma, lymphoma, malign carcinoid, melanoma, rectal carcinoma, ovarian carcinoma, mamma carcinoma, and prostate carcinoma.

12. (Currently amended) The method of claim ~~1~~4 wherein said cancerous tumor is selected from the group consisting of colon cancer, rectal cancer, pancreatic cancer, stomach cancer and lung cancer.

13 – 25. (Canceled)

26. (Currently amended) The method of claim ~~1~~4 further comprising administering to said patient 5-fluorouracil (5-FU) at a dosage within a range of about 0.1-1,000 mg.